BGM Group Ltd. (BGM)
NEGATIVEFundamental
~22
Kurs
$0.25
Marktkapitalisierung
$100M
Teil 1 · Was das Unternehmen wert ist
Übersicht
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Begrenzte Finanzdaten verfügbar (37 % der Kennzahlen). Scores spiegeln möglicherweise die Fundamentaldaten dieses Unternehmens nicht genau wider.
Bilanz & Liquidität
Umsatz
$74M
Nettogewinn
$-39M
Freier Cashflow
-
Gesamtes Eigenkapital
$742M
Gesamtverbindlichkeiten
-
Current Ratio
1.24
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$0.10
Aktueller Kurs
$0.25
Sicherheitsmarge
-154.5%
Innerer-Wert-Spanne
$0.08 - $0.13
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-7.0%
P/B-Verhältnis
0.15
P/FCF
31.32
Bruttomarge
16.6%
ROIC
-1.8%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-1.8%
WACC
14.5%
ROIC − WACC
-16.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (2)
- P/B Ratio 0.15
- Current Ratio
Nicht bestanden (8)
- Price CAGR -54.38%
- ROIC -1.8%
- Gross Margin 16.6%
- P/FCF 31.32
- DCF valuation (Overvalued)
- ROE -7.0%
- Revenue Growth 5Y -5.4%
- Piotroski F-Score 0/9
Nicht verfügbar (17)
- EPS data insufficient
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (need 2+ years)
- Net Margin Trend (invalid data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Ms. Huandi Zhao | Co-Chief Executive Officer & Director | 40 |
| Ms. Li Hong | Co-Chief Executive Officer | - |
| Ms. Yaxuan Zhai | Chief Financial Officer | 30 |
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for BGM, sourced from Markets Gazette.